We will be totally self-sufficient for the supply of medicines to American patients.” AstraZeneca CEO Pascal Soriot on the ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

Good morning. Thirty-three days. That’s how long it took from the time AstraZeneca CEO Pascal Soriot greeted Virginia Governor Glenn Youngkin in his London office to announcing a $4 billion ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

Markets reflect a widespread belief that the US president always chickens out on trade measures. AstraZeneca’s plan to invest ...

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...

Pascal Soriot, Director at Agilent Technologies (NYSE:A), reported an insider buy on May 23, according to a new SEC filing. What Happened: Soriot made a significant move by purchasing 1,677 shares ...

AstraZeneca CEO Pascal Soriot is plotting a shift of the company’s primary stock listing from the London to the U.S., according to The Times.

Pascal Soriot has led AstraZeneca as CEO since 2012, guiding the company’s transformation into a global leader in science-driven innovation with a strong pipeline and substantial growth.